Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: an evolving issue

Immunotherapy. 2019 Apr;11(5):365-368. doi: 10.2217/imt-2018-0204.

Authors

Giandomenico Roviello¹, Daniele Generali^{2

3}, Anna Ianza⁴

Affiliations

¹ Translational Oncology Unit, Department of Health Sciences, University of Florence, viale Pieraccini, 6, 50139 Florence, Italy.
² Department of Medical, Surgery & Health Sciences, University of Trieste, Trieste, Italy.
³ Breast Cancer Unit & Translational Research Unit, ASST Cremona, Cremona, Italy.
⁴ Department of Medical, Surgery & Health Sciences, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy.

PMID: 30786842
DOI: 10.2217/imt-2018-0204

No abstract available

Keywords: PD-1; PD-L1; Phase II; end points; immunotherapy.

Publication types

Editorial

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use*
Clinical Trials, Phase II as Topic
Humans
Immunotherapy*
Neoplasms* / immunology
Neoplasms* / pathology
Neoplasms* / therapy

Substances

Antineoplastic Agents, Immunological